search
Back to results

Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma

Primary Purpose

Glioma

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Early START visit using checklist over telephone or zoom
Sponsored by
University of Rochester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Glioma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • New pathologic diagnosis of WHO grade III or IV glioma within four months of consent
  • English speaking

Exclusion Criteria:

  • Severe cognitive dysfunction or aphasia precluding discussion of advanced care planning issues

Sites / Locations

  • University of RochesterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Early STructured Advanced care Referrals by Telehealth

Arm Description

Early START visit using checklist over telephone or zoom: A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma.

Outcomes

Primary Outcome Measures

Advanced Directive Completion Rate
Percentage of patients who complete an advanced directive by the third oncology visit

Secondary Outcome Measures

Early START visit completion
Percentage of Early START (Early STructured Advanced care Referrals by Telehealth) visits completed by the third oncology visit
Checklist use
Percentage of providers who use the checklist
Duration of visit
Duration of time in minutes
Advanced Care Directive Completion by patient vs proxy
Percentage of completed Advanced Care Directives completed by proxy (rather than by the patient)
Chemotherapy use at end of life
Percentage of patients that were treated with chemotherapy within 14 days of death
Hospice enrollment
Percentage of patients who were enrolled in hospice >7 days prior to death
Palliative care and/or hospice involvement at end of life
Percentage of patients who received a palliative care or hospice consult prior to death
Setting of end of life
Percentage of patients for whom setting of death was consistent with their wishes

Full Information

First Posted
August 28, 2020
Last Updated
December 6, 2022
Sponsor
University of Rochester
search

1. Study Identification

Unique Protocol Identification Number
NCT04543201
Brief Title
Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
Official Title
Early Telehealth Visits for Discussion of Advanced Directives for Patients Newly Diagnosed With High Grade Glioma: Impact on Patient Care and Satisfaction
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 26, 2021 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
August 19, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Rochester

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. It is important for patients with HGG to discuss and document their wishes at the end of life. However, many of these patients experience early changes in cognition which impede their decision-making. For this reason, these patients should have early discussions with their providers. However, implementation of this remains challenging in clinical practice. In this study, we will create an Early STructured Advanced care Referrals by Telehealth (Early START) visit for patients soon after their initial oncology visit. A checklist and pre-visit guide were developed to help guide the visit for both the provider and patient. Providers will receive special training in running these visits. Caregivers and/or family members will be encouraged to participate. Visits will be done using video or telephone and recorded. For patients who do not have access to technology for these visits, it will be provided. After the visit, patients, caregivers and/or family who participated, and providers will fill out surveys to address feasibility of having these extra visits and improve the visits for future. Patients will be followed until death. Caregivers and/or family who participated will be asked about whether end of life was in line with the patient's wishes. We will also use the patient's medical record to assess other aspects of end of life. We will compare end of life outcomes with other similar patients treated at our center.
Detailed Description
High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. Discussion and documentation of an advance care plan are needed to achieve end of life goals that are concordant with a patient's wishes. Early cognitive dysfunction in brain tumor patients can impede patients from making decisions about their own care. Patients with HGG, therefore require discussion and documentation of end of life goals early in their disease course, but implementation of this has been elusive. In this study, we will integrate an Early STructured Advanced care Referrals by Telehealth (Early START) visit into standard neuro-oncologic care prior to initiation of adjuvant chemotherapy in patients with HGG. Multi-disciplinary providers including physicians, advanced practice providers, and nurses will undergo an in-service by palliative care experts to perform Early START with a standardized checklist followed by periodic training sessions. Fifty patients with HGG will be enrolled over a 12-month period. They will receive a pre-visit educational guide to increase literacy regarding advance directives (AD) followed by a provider-led Early START visit that will be recorded. Post-visit assessments will address patient and caregiver perspectives on the intervention, patient and caregiver knowledge, patient satisfaction and patient-reported anxiety measures. A provider questionnaire will assess length of visit, adherence to the checklist and AD outcomes of the visit. Patients will be followed until death. End of life quality measures and concordance of death with goals of care will be assessed using a combination of caregiver surveys and the electronic medical record. These outcomes will be compared to historical controls treated at our center from 2010-2015. Specific Aims: Aim 1a. To determine the effectiveness of Early START as measured by AD documentation. Aim 1b. To determine the utility of Early START as measured by timing of hospice enrollment at the end of life and place of death concordant with the patient's goals. Hypothesis: As our primary aim, we hypothesize that Early START will increase the percentage of AD documentation by the 3rd oncology visit from 51% to 80%. As secondary outcomes, we hypothesize that it will decrease the percentage of AD that are completed by proxy from 45% to 25%, will improve end of life quality measures as compared to our published historical controls and that the majority of patients who undergo Early START will die in a setting of their choosing. Aim 2a. To demonstrate the feasibility of Early START as measured by the percent of visits completed prior to the third oncology visit, adherence to a pre-specified checklist, and length of time to complete the visit. Aim 2b. To optimize the Early START intervention by incorporating patient/caregiver and provider feedback. Hypothesis: We hypothesize that 80% of visits will be completed using telehealth by the 3rd oncology visit, 80% of providers will utilize the pre-specified checklist and that average visit duration will be less than one hour.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioma

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Early STructured Advanced care Referrals by Telehealth
Arm Type
Experimental
Arm Description
Early START visit using checklist over telephone or zoom: A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma.
Intervention Type
Behavioral
Intervention Name(s)
Early START visit using checklist over telephone or zoom
Intervention Description
Prior to visit subject receives pre-visit educational guide and copy of advance directive form Follow up surveys: Immediate: provider feedback survey 2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey After subject death: caregiver/family survey
Primary Outcome Measure Information:
Title
Advanced Directive Completion Rate
Description
Percentage of patients who complete an advanced directive by the third oncology visit
Time Frame
Time of diagnosis to 3rd oncology visit at an average of 4 months
Secondary Outcome Measure Information:
Title
Early START visit completion
Description
Percentage of Early START (Early STructured Advanced care Referrals by Telehealth) visits completed by the third oncology visit
Time Frame
Time of diagnosis to 3rd oncology visit at an average of 4 months
Title
Checklist use
Description
Percentage of providers who use the checklist
Time Frame
Time of Early START visit [on average between 3-4 months after diagnosis]
Title
Duration of visit
Description
Duration of time in minutes
Time Frame
Duration of visit [average 60 min]
Title
Advanced Care Directive Completion by patient vs proxy
Description
Percentage of completed Advanced Care Directives completed by proxy (rather than by the patient)
Time Frame
Time of diagnosis to death up to 5 years after registration
Title
Chemotherapy use at end of life
Description
Percentage of patients that were treated with chemotherapy within 14 days of death
Time Frame
Time of diagnosis to death up to 5 years after registration
Title
Hospice enrollment
Description
Percentage of patients who were enrolled in hospice >7 days prior to death
Time Frame
Time of diagnosis to death up to 5 years after registration
Title
Palliative care and/or hospice involvement at end of life
Description
Percentage of patients who received a palliative care or hospice consult prior to death
Time Frame
Time of diagnosis to death up to 5 years after registration
Title
Setting of end of life
Description
Percentage of patients for whom setting of death was consistent with their wishes
Time Frame
Time of diagnosis to death up to 5 years after registration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: New pathologic diagnosis of WHO grade III or IV glioma within four months of consent English speaking Exclusion Criteria: Severe cognitive dysfunction or aphasia precluding discussion of advanced care planning issues
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Hardy, MD
Phone
585-273-4096
Email
Sara_Hardy@URMC.rochester.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Serventi, NP
Email
Jennifer_Serventi@URMC.rochester.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Hardy, MD
Organizational Affiliation
University of Rochester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Ellis
Phone
585-275-2224
Email
Sara_Hardy@URMC.Rochester.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma

We'll reach out to this number within 24 hrs